Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision Biosciences, Inc. (DTIL) is a biotechnology innovator advancing the ARCUS genome editing platform for therapeutic and agricultural solutions. This page serves as the definitive source for verified company news, providing investors and industry professionals with timely updates on scientific milestones and corporate developments.
Access consolidated information on regulatory filings, research breakthroughs, and strategic partnerships directly impacting DTIL's position in the genome editing sector. Our curated feed includes earnings announcements, clinical trial updates, and technology licensing agreements, enabling informed analysis of the company's progress.
Key focus areas include ARCUS platform advancements in gene therapy programs, allogeneic CAR-T developments, and agricultural biotechnology applications. Users can track patent approvals, peer-reviewed study publications, and executive leadership updates through our chronologically organized news archive.
Bookmark this page for streamlined access to Precision Biosciences' official communications and third-party analysis. Check regularly for updates on how DTIL's precision gene editing technology continues to shape the future of genomic medicine and sustainable agriculture.
iECURE reported positive preliminary results from its Phase 1/2 OTC-HOPE clinical trial for ECUR-506, a gene editing therapy for ornithine transcarbamylase (OTC) deficiency. The first infant treated showed a complete clinical response at the lowest dose level, demonstrating successful removal of ammonia scavenging medicines and normalization of protein intake after three months, with results maintained through the six-month study period.
The treatment was generally well-tolerated, with only asymptomatic transaminitis occurring at four weeks, which resolved within four weeks through immunosuppressive therapy. The OTC-HOPE trial is currently enrolling patients across four regions (US, UK, Spain, and Australia), with complete data readout expected in 1H 2026. The therapy targets neonatal onset OTC deficiency, affecting over 1,000 births globally per year.
ECUR-506 utilizes two AAV vectors: an ARCUS® nuclease vector licensed from Precision BioSciences (DTIL) and a donor vector for OTC gene insertion.
Precision BioSciences (DTIL) has received Clinical Trial Application approval in Hong Kong for PBGENE-HBV, marking the first in vivo gene editing approach for chronic hepatitis B in Hong Kong and their second CTA approval in 2024. The ELIMINATE-B Phase 1 trial is actively recruiting patients in Moldova and expanding to Hong Kong.
PBGENE-HBV, utilizing the ARCUS® platform, is designed to cure chronic hepatitis B by eliminating cccDNA and inactivating integrated HBV DNA in hepatocytes. The therapy targets a viral site prevalent across all HBV genotypes, particularly relevant for Asia where over 400,000 individuals in Hong Kong live with chronic hepatitis B.
The company expects to report clinical data throughout 2025 and anticipates a U.S. investigational new drug (IND) application in 2025.
Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company, has announced its participation in two upcoming investor conferences in November 2024. The company will take part in the JonesTrading Virtual Genetic Medicine Day on November 25 at 11:00 AM ET, participating in a panel discussion titled 'Next Generation of Gene Editing; Going Beyond "Cas"'. Additionally, Precision will present at AussieMit on November 29 at 2:50 PM AEDT, discussing 'Emerging Therapies'. The JonesTrading event webcast will be available on Precision's investor website, with replay access for approximately 30 days.
Precision BioSciences (DTIL) has presented preclinical data for PBGENE-HBV, its gene editing therapy for chronic hepatitis B, and outlined its Phase 1 ELIMINATE-B trial design. The preclinical data showed 99% viral DNA editing in non-human primates, effective hepatocyte distribution, and sustained declines in viral biomarkers. The ELIMINATE-B trial will evaluate up to 45 HBeAg-negative patients across five countries, with data expected throughout 2025. The company has received clearance to begin trials in Moldova, with additional regulatory applications pending. The therapy targets approximately 300 million people globally affected by chronic hepatitis B, addressing an unmet need in a multi-billion-dollar market where current treatments achieve functional cure in less than 3% of patients.
Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company, announced it will release its financial results for the third quarter of 2024 on November 4, 2024. The company utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies aimed at sophisticated gene edits. Along with the financial results, Precision BioSciences will also provide a business update.
Precision BioSciences (Nasdaq: DTIL) announced a virtual Hepatitis B Investor Event scheduled for November 15, 2024. The event will feature Key Opinion Leaders and members of Precision's Hepatitis Scientific Advisory Board discussing the current hepatitis B treatment landscape, which only achieves 1-3% functional cure rates. The presentation will focus on PBGENE-HBV, their gene editing approach targeting cccDNA elimination and HBV DNA inactivation. The company will present final preclinical safety data and phase 1 clinical trial plans following Clinical Trial Application approval in Moldova.
Precision BioSciences (Nasdaq: DTIL) presented preclinical data at the ESGCT 31st Annual Congress showcasing their ARCUS platform's capability for high-efficiency gene editing through homology-directed repair (HDR). The research demonstrated gene insertion rates exceeding 85% in T cells and 39% in non-dividing primary human hepatocytes.
The ARCUS platform showed versatility in DNA editing, achieving all twelve possible base changes, specific base removal and insertions, and whole gene replacements. This capability extends beyond current limitations of base editors and prime editors, potentially offering broader therapeutic applications for diseases requiring function restoration.
Precision BioSciences (NASDAQ: DTIL) has received its first Clinical Trial Application (CTA) approval in Moldova for PBGENE-HBV, marking the first in vivo gene editing program for chronic hepatitis B virus to enter global clinical trials. The program aims to cure chronic hepatitis B by eliminating cccDNA and inactivating integrated HBV DNA in hepatocytes using the proprietary ARCUS® platform. PBGENE-HBV delivers nuclease-encoding mRNA to the liver via lipid nanoparticles, targeting the HBV viral genome. The company is pursuing additional CTA and IND approvals globally to accelerate trial enrollment, aiming to provide a potential cure for nearly 300 million patients living with chronic hepatitis B.
Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company, has announced its participation in two upcoming investor conferences. The company will be part of a panel discussion titled 'Expanding Platform Potential' at the Longwood Boston CEO Conference on October 28, 2024, at 11:10 AM ET.
Additionally, Precision BioSciences will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 11, 2024, at 3:00 PM ET at the InterContinental Boston. A live webcast of this event will be available on the company's website, with an archived replay accessible for approximately 30 days after the event.
Precision BioSciences utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits.
Precision BioSciences (Nasdaq: DTIL), an advanced gene editing company, announced a poster presentation at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress in Rome, Italy, from October 22-25, 2024. The company utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion.
The presentation, titled 'High-efficiency homology-directed insertion into the genome using engineered homing endonucleases', will be delivered by Dr. Adam Mischler, Senior Scientist at Precision BioSciences Gene Discovery. The poster (Number #PO678) will be presented on Thursday, October 24, 2024, from 6:00-7:30pm CEST. This presentation highlights Precision BioSciences' advancements in gene editing technology, particularly in addressing diseases where a defective gene requires the expression of a new DNA sequence.
FAQ
What is the current stock price of Precision Biosciences (DTIL)?
What is the market cap of Precision Biosciences (DTIL)?
